Company: NCEL
Filing Date: 2025-03-31
Form Type: F-4/A
Source: 0001213900-25-026428
Chunk: 263

Company: NewcelX Ltd.
Filing Date: 2025-03-31
Form: F-4/A
Chunk 263
---
 has the potential to advance its product candidates rapidly through early -stageclinical trials, while carrying an overall lower development risk. A lower development risk, NLS believes, exists with respect to the development of its lead product candidate, Quilience, and follow -onproduct candidate, Nolazol, due to their use of mazindol as the active ingredient, which was previously approved and marketed in the United States, Japan and Europe to manage exogenous obesity (obesity caused by overeating). The Merger Agreement provides that, upon the terms and subject to the conditions thereof, following and subject to the Closing, NLS shall work diligently to dispose of any Legacy Assets, which excludes the DOXA platform. The DOXA platform includes AEX -041. It is important to note that AEX -041is currently in the preclinical stage of development. This means that the candidate is undergoing early laboratory studies to evaluate its safety profile and pharmacological properties, and it has not yet been tested in human clinical trials. Consequently, its efficacy, safety, and potential for regulatory approval remain subject to further research and development. It is expected that the proceeds from any such disposition will be distributed to the shareholders and warrantholders of NLS as of immediately prior to the Effective Time pursuant to the terms and conditions of the CVR Agreement, subject to the adjustments set forth therein. NLS was incorporated on June 10, 2015 as a Swiss limited company. NLS’s registered office and principal executive offices are located at The Circle6, 8058 Zurich, Switzerland. NLS’s telephone number in Switzerland is +41.44.512.2150 and its website address is https://nlspharma.com. The information contained on, or that can be accessed through, NLS’s website is not part of this proxy statement/prospectus. The website address has been included in this proxy statement/prospectus solely as an inactive textual reference. After the consummation of the Merger, NLS’s principal executive office will remain at The Circle6, 8058 Zurich, Switzerland, Tel: +41.44.512.2150. Incorporation of Information by Reference The foregoing information concerning NLS does not purport to be complete. The information concerning the business of NLS is provided by reference to the information set forth in NLS’s Annual Report on Form 20 -Ffor the year ended December 31, 2023, which is attached to this document as Annex F and is incorporated